Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5323441+ bevacizumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO5323441 + bevacizumab [Avastin] | DRUG | Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks |
| bevacizumab [Avastin] | DRUG | Efficacy-Finding part: 10 mg/kg intravenously once every two weeks |
Inclusion Criteria: * Adult patients, \>/=18 years of age * Histologically confirmed glioblastoma * Radiographic demonstration of disease progression by Response Assessment in Neurooncology (RANO) criteria following prior therapy * Availability of at least 1 formalin-fixed paraffin-embedded tumor t...
RO5323441 is an investigational small molecule being studied for use in oncology, specifically for hepatocellular carcinoma, glioblastoma multiforme, colorectal cancer, and ovarian cancer. It has been evaluated in Phase 1 clinical trials, both as a single agent and in combination with other therapies.
RO5323441 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored Phase 1 clinical trials of this investigational oncology drug.
RO5323441 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All completed trials for this asset are Phase 1 studies.
RO5323441 has been studied in three completed Phase 1 trials: NCT01148758 in metastatic treatment-refractory colorectal or ovarian cancer, NCT01308684 in recurrent glioblastoma in combination with bevacizumab, and NCT01308723 in hepatocellular carcinoma in combination with sorafenib.
RO5323441 is an investigational small molecule developed by Roche. No alternative names for this drug have been reported in clinical trial records. It is distinct from the combination agents it has been studied with, such as bevacizumab and sorafenib.